Taiwan's health care market boosted by aging population

3 September 2012

Although a challenge for the national government, a growing aging population combined with the country’s universal health care system means that Taiwan’s health care market can expect to expand in the future, says the latest report by industry experts GlobalData.

According to the latest study, Taiwan’s pharmaceutical industry is predicted to climb from a value of $3.8 billion in 2011 to $4.8 billion by 2020, while the medical devices industry is expected to reach $3 billion by the end of the decade from a 2011 valuation of $1.9 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Generics